12.Egan JM, Clocquet AR, Elahi D 2002 The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondia-betic state to type 2 diabetes. J Clin Endocrinol Metab 87:1282–1290 13.Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD 2003 Syn- thetic exendin-4 (exenatide) significantly reduces postprandial andfasting plasma glucose in subjects with type 2 diabetes. J Clin En-docrinol Metab 88:3082–3089 14.Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD 2005 Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am JHealth Syst Pharm 62:173–181 15.Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fine- man M, Taylor K 2007 Effects of once-weekly dosing of a long- acting release formulation of exenatide on glucose control and bodyweight in subjects with type 2 diabetes. Diabetes Care 30:1487–1493